Legion Therapeutics builds dual-use drug development infrastructure that targets warfighter performance and civilian health priorities. Its pipeline includes Ln-101, a circRNA therapy for muscle recovery, and Ln-102, a bioscavenger for fentanyl prophylaxis, both advanced through modular AI and robotics from target discovery to pre-IND stages.
Funding
Funding not disclosed
Founders
Product
Problem
U.S. military readiness is constrained by lengthy training timelines, muscle loss, and vulnerability to chemical threats such as synthetic opioids, which also drive a civilian overdose crisis. Conventional therapeutics development is slow and often lacks the dual-use focus needed to serve both warfighter and public health needs.
Solution
Legion Therapeutics provides a dual-use drug development infrastructure that scales non-dilutive defense capital to de-risk therapeutics relevant for warfighters and global markets. The company leverages modular AI and robotics capabilities to move candidates from target identification through preclinical stages, enabling faster, more efficient development. Its pipeline includes Ln-101, a circular RNA therapy that selectively delivers Ln-1 to skeletal muscle to promote hypertrophy and repair without systemic hormonal effects. Ln-102 is a bioscavenger designed to protect against fentanyl and related synthetic opioid exposure. A third candidate, a buccal appetite regulator, targets visceral fat reduction and appetite control to optimize health and lifespan.
Target Audience
Primary customers are U.S. Department of Defense entities and military medical research organizations seeking therapeutics for warfighter readiness, alongside civilian healthcare markets addressing opioid overdose and metabolic health.
Features
- Ln-101: circRNA-based therapy delivering Ln-1 selectively to skeletal muscle via systemic administration for hypertrophy, repair, and vascularization without elevating systemic hormone levels
- Ln-102: bioscavenger for prophylaxis against fentanyl and its analogs, addressing the leading cause of death for Americans aged 18-45
- Buccal appetite regulator for reducing visceral fat and controlling excessive hunger
- Modular AI-driven pipeline from target discovery to pre-IND stage with integrated robotics capabilities
- Dual-use positioning covering military casualty reduction and civilian medical spin-outs